Executive Summary
The Swiss Federal Council is endangering core competitive advantages through regulatory tightening and tax changes. Swiss companies pay wages 50–70% above the European average and bear high infrastructure costs; these have previously been offset by low taxes, lean regulation, and high legal certainty. These advantages are eroding: tax advantage over Frankfurt lost for incomes above 150,000 francs, OECD minimum tax reduces corporate taxation advantage, Basel III increases financing costs. Further burdens loom from stricter capital requirements and the Corporate Responsibility Initiative. Pharmaceutical and financial sectors are under pressure.
Persons
- Ruedi Noser (former Zurich States Councillor, entrepreneur, FDP)
Topics
- Swiss location policy
- Regulatory burden
- Corporate taxation
- Financial sector
- Pharmaceutical location
Clarus Lead
The guest commentary points to a strategic failure: as global risks (wars, trade conflicts, AI disruption) increase, the federal government is precisely weakening those economic sectors that secure prosperity. This contradicts the stated goal of defending competitiveness. The German example warns: two decades of regulatory overburden led to stagnation and innovation loss—a scenario Switzerland should avoid.
Detailed Summary
The criticism focuses on three areas of action. Corporate taxation: The tax advantage between Zurich and Frankfurt has been effectively eliminated for incomes of approximately 150,000 francs and above; the OECD minimum tax structurally leveled corporate taxation advantages. Financial sector: Basel III tightening has noticeably increased financing costs with negative consequences for investment and growth; a further capital requirements tightening for internationally active banks is imminent.
Regulatory burden: The indirect counter-proposal to the Corporate Responsibility Initiative (submitted for consultation) in places goes beyond EU law and means additional bureaucratic and financial burdens—although its effectiveness and benefits are themselves disputed even in the EU. Pharmaceutical location: US tariffs and EU reference pricing regulations disadvantage small markets like Switzerland; market launches of innovative medicines become less attractive. Access to new therapies has demonstrably already deteriorated. The Federal Council established a working group; success remains uncertain.
The author diagnoses a credibility problem in administration and politics: the assumption that the economy can be burdened arbitrarily without consequences. The historical parallel to Germany (1990s as industrial model, today stagnating) underscores the risk of long-term prosperity loss.
Key Statements
- Swiss location advantages (low taxes, lean regulation, legal certainty) are being actively dismantled, while structural cost disadvantages (wages, rents) remain.
- OECD minimum tax, Basel III, and planned corporate liability cumulatively weaken the financial and corporate sectors.
- The pharmaceutical location loses attractiveness due to US tariffs and EU pricing regulations; access to new therapies deteriorates.
- Germany parallel: regulatory overburden led to two decades of stagnation and innovation loss.
- Strategic failure: in global uncertainty, backbone sectors (finance, pharma, exports) are being weakened instead of strengthened.
Critical Questions
Evidence (Data Quality): What empirical evidence exists for the claimed causality between Basel III implementation and reduced investment growth? Are financing cost increases independently measurable or a consequence of multiple factors?
Evidence (Source Validity): The author cites "demonstrably deteriorated" access to new therapies—which studies or datasets concretely support this claim?
Conflicts of Interest: The author is an entrepreneur and long-serving FDP politician. To what extent does the commentary reflect interest-bound positions against progressive regulation (taxes, corporate responsibility)?
Causality/Alternatives: Is the erosion of location advantages attributed exclusively to regulatory measures? What share do global megatrends (AI, deglobalization) account for versus national policy?
Feasibility/Side Effects: If the Corporate Responsibility Initiative and Basel III were reversed—what societal or financial stability risks would emerge? Are these costs accounted for?
Causality: The Germany parallel (1990s model → stagnation) is drawn, but were German errors specifically identified? Regulation alone or also other factors (energy transition, demographics)?
Evidence: Are the wage premiums (50–70% above European average) currently measured or a historical reference? Have they changed in recent years?
Feasibility: The pharmaceutical location working group is mentioned—what concrete instruments could help without violating international agreements?
Bibliography
Primary Source: The Federal Council Is Squandering Switzerland's Location Advantages – NZZ
Verification Status: ✓ 15.04.2026
This text was created with the support of an AI model. Editorial responsibility: clarus.news | Fact-checking: 15.04.2026